DUBLIN--(BUSINESS WIRE)--The "Global Parkinson's Disease Drugs Market - Growth, Trends and Forecast 2017 - 2022" report has been added to Research and Markets' offering.
According to an estimation, approximately 10 million people suffer from Parkinson's disease. This number keeps on increasing every year. At least one million of US citizens are suffering from this disease and this appends to around 60 thousand every year. A Parkinson's patient spends somewhere around $2,500 per year on medications to aid in ease of life. The disease prevalence increases with increase in the average age of the population.
The market will face corrosion due to entry of generics as well as due to patient expiries for key products, including Neupro, Azilect and Stalevo. The market however has a lot of unmet needs. Lack of a curative therapy in the current market is one of the reasons for continuous research and thus, new products are being launched every year. Four levodopa formulations might enter the market during this period thus causing market growth. However, due to the lack of clearly established clinical trial methodologies, replication of the benefits demonstrated by neuroprotective agents in the laboratory to human trials has proved challenging. More importantly, due to an incomplete understanding of the underlying mechanisms that cause the disease, a viable therapeutic target to halt or slow disease progression is currently not in scope, which limits the effectiveness of current product development programs.
The current market lacks curative therapy and hence bringing innovative products and tapping the emerging economy will be a great opportunity for the market. The key players in the market are Merck & Co., Impax Laboratories, Abbvie Pharmaceuticals, Mylan Laboratories, Boehringer Ingelheim, GlaxoSmithKline, UCB, Somerset Pharmaceuticals, Teva NS, Pfizer, Novartis, Janssen, Allergan and Acadia.
Companies Mentioned
- Abbvie
- Acadia
- Allergan
- Boehringer Ingelheim
- GlaxoSmithKline
- Impax Laboratories
- Janssen
- Merck & Co.
- Mylan Laboratories
- Novartis
- Pfizer
- Somerset Pharmaceuticals Inc
- Teva Neurosciences
- UCB
Key Topics Covered:
1. Introduction
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview and Industry Trends
6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
7. Global Parkinson's Disease Market - Segmentation
8. Global Parkinson's disease market by Geography - Regional shares and forecast
9. Competitive Landscape
10. Company Profiles
11. Analyst Outlook for Investment Opportunities
12. Future Outlook of the Market
For more information about this report visit https://www.researchandmarkets.com/research/q6dmq7/global
